Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
News|Articles|September 18, 2024
Conference Compendium: The Top 10 Takeaways From ESMO 2024
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci
ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.
Advertisement
Advertisement
At the
Related to this article
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
Advertisement
Advertisement